Xpovio
Payments companies reported to CMS as associated with Xpovio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xpovio, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xpovio
These are the largest totals companies reported as associated with Xpovio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Hakan Kaya | Spokane, WA | Medical Oncology | $147,926.02 |
| Taral Patel | Columbus, OH | Hematology & Oncology | $121,359.12 |
| Mojtaba Akhtari | Omaha, NE | Hematology & Oncology | $114,753.61 |
| Rahul Naik | Los Angeles, CA | Hematology & Oncology | $88,649.86 |
| James Berenson | West Hollywood, CA | $78,665.34 | |
| Suresh Ratnam | Mcallen, TX | Medical Oncology | $68,657.99 |
| Hamza Hashmi | Charleston, SC | Hematology (Internal Medicine) | $68,264.96 |
| Kelly Mccaul | Sioux Falls, SD | Hematology & Oncology | $65,460.85 |
| Rajesh Behl | Berkeley, CA | Hematology & Oncology | $61,635.53 |
| John Renshaw | San Antonio, TX | Hematology & Oncology | $58,332.07 |
Prescribed Xpovio?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.